CELLINK

Name: CELLINK
Address: Långfilsgatan 1, Gothenburg, 41277, SE
Telephone: +18332355465

CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology.

With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories,

including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine. Visit cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.

18/06/2026

While animal models remain widely used, their ability to predict human toxicity is limited, driving the shift toward new approach methodologies (NAMs) and more human-relevant models.
Bioprinting is playing a key role in this transformation.

If you missed our live session, you can now watch the webinar on demand featuring Prof. Shaochen Chen and Dr. Ting-Yu Lu, who explore how advanced biofabrication is shaping next-generation liver models, from scalable, patient-specific approaches to perfusable, multicellular systems using DLP bioprinting on the BIONOVA X.

What you will learn:
• Why bioprinted tissues are emerging as powerful NAMs
• How bioprinting, stem cells, and AI are advancing liver models
• Strategies to control tissue architecture and cell–matrix interactions
• How perfusion supports long-term function and predictive toxicology

▶️ Watch the recording now https://eu1.hubs.ly/H0wfpF00

10/06/2026

Glioblastoma research is limited by extreme differences from patient to patient. These differences make these tumors difficult to model in vitro, impeding the development of effective therapies. Traditional 2D cell cultures cannot capture the complex tumor microenvironment, while generic 3D models introduce variables that limit their clinical relevance.

To solve this issue, researchers at Wake Forest School of Medicine have developed a custom hyaluronic acid and gelatin-based hydrogel that closely mimics the brain's extracellular matrix. By embedding cells from several patient samples, they created patient-derived tumor constructs (PTCs). Using a BIO X bioprinter as proof of concept, the team automated the precise dispensing of cell-loaded ~10 μL droplets into 48-well plates, showing the potential for rapid, high-throughput fabrication of patient-specific tumor models.

These patient-derived tumor constructs exhibited high cell viability and maintained the genomic and molecular fidelity of the original tumors. RNA sequencing confirmed that the 3D models preserved critical molecular subtypes, avoiding the artificial shifts seen in conventional 2D cultures. Drug response testing showed stable, patient-specific outcomes that match with clinical expectations across glioma grades.

This study highlights the value of patient-derived tumor constructs as a superior method for patient-specific oncology, offering reliable translational data without the significant genetic drift seen in 2D cell culture.

Congratulations to the research team on this excellent contribution to precision medicine and cancer research!

Read the full publication here: https://eu1.hubs.ly/H0w2bBh0.

08/06/2026

We are excited to be on-site at EACR, connecting with the cancer research community driving the future of oncology.

📍 Meet our team at booth #56 to explore how 3D bioprinting enables more advanced tumor models within NAMs and MPS frameworks, bringing greater complexity, spatial control, and reproducibility to cancer research.

Can't attend? Schedule a call with an expert: https://eu1.hubs.ly/H0v_mpx0

04/06/2026

We’re excited to attend EACR 2026 (June 8–11) and engage with the cancer research community driving the future of oncology, together with our local partners Per-Form Hungária.

As the field continues to shift toward New Approach Methodologies (NAMs) and Microphysiological Systems (MPS), the focus is on developing more predictive, human-relevant tumor models.

3D bioprinting enables the next generation of these models, creating more advanced tumor systems with precise spatial organization, dynamic perfusion, and high reproducibility. This allows researchers to better capture tumor complexity and generate more predictive insights into tumor behavior and therapeutic response.

At our booth, we’ll showcase how bioprinting supports:
🔬 Physiologically relevant 3D tumor models
🧬 Tunable microenvironments and multicellular complexity
💊 More predictive drug screening workflows
🧫 Reproducible and scalable model development
Join us to explore how these approaches are shaping the next generation of cancer research and connect with our team to discuss your applications.

📍 Visit us at Booth #56
➡️ Stop by for demo and meet our experts

01/06/2026

While animal models remain widely used, their ability to predict human toxicity is limited, driving the adoption of new approach methodologies (NAMs). Bioprinting is playing a key role in this shift, enabling more physiologically relevant, human-based tissue models.

In this live webinar, Prof. Shaochen Chen and Dr. Ting-Yu Lu will present how advanced biofabrication is shaping next-generation liver models, from scalable, patient-specific approaches to perfusable, multicellular systems developed using DLP bioprinting on the BIONOVA X.

What you’ll learn:
• Why bioprinted tissues are emerging as powerful NAMs
• How bioprinting, stem cells, and AI are advancing liver models
• Strategies to control tissue architecture and cell–matrix interactions
• How perfusion supports long-term function and predictive toxicology

🗓️ Join us tomorrow 2nd June → Register now https://eu1.hubs.ly/H0vMWhC0

27/05/2026

Hello MPS World Summit 👋
We’re on the ground and ready to connect! Visit our booth ( #527) to meet Zack Graham, Devanshi Shanghavi, Wei Zhu and Shreyas Gaikwad and learn how 3D bioprinting is enabling reproducible, perfusable MPS tissue models with more realistic biological cues.

Not attending? Learn more here: https://eu1.hubs.ly/H0vGv1m0

15/05/2026

From 2D cell culture to engineered 3D microenvironments - closing the gap to human physiology.
At Life Science Live on May 19 in Utrecht, Dr. Marco Domingos (University of Manchester) will present:
“Beyond 2D Cell Culture: Engineering Skeletal Tissue Microenvironments through 3D Bioprinting.”

Working with CELLINK technologies, he will show how 3D bioprinting recreates key extracellular matrix features to enable more physiologically relevant models. By designing biomaterials and bioinks that mimic tissues like bone and cartilage, his approach supports controlled cell interactions, guided stem cell behavior, and structured 3D models that better reflect native tissue complexity.

Our partner, Future Lab Innovations will be there. Stop by their booth to connect and explore 3D bioprinting workflows further.

13/05/2026

As regulatory momentum grows around new approach methodologies (NAMs), the need for predictive, human-relevant models has never been greater. Join our upcoming webinar to explore how bioprinted human tissues are advancing new approach methodologies (NAMs) and helping reduce reliance on animal testing.

Hear from Prof. Shaochen Chen (UC San Diego) on decades of innovation in biofabrication and a new ARPA-H–funded initiative for patient-specific bioprinted liver models. Plus, Dr. Ting‑Yu Lu presents a perfusable, multi-cellular liver model combining iPSC-derived cells, advanced hydrogels, and DLP bioprinting on the BIONOVA X.

You’ll learn:
• Why bioprinting is gaining traction as a NAM
• How AI, stem cells, and bioprinting are shaping next-gen liver models
• Strategies for achieving precise tissue architecture and function

Register now: https://eu1.hubs.ly/H0vj4HJ0

05/05/2026

We’re excited to have collaborated with Sartorius on a new technical note that demonstrates an integrated workflow which addresses key bottlenecks in scaling and standardizing organoid assays.

By pairing CELLINK’s BIO ONE automated biodispenser with Sartorius | Incucyte® Live-Cell Analysis Systems, the workflow enables uniform dispensing of 5 µL cell‑laden Matrigel® domes across a 96‑well plate in ~6 minutes, while supporting continuous monitoring of organoid growth, morphology and treatment response.

To assess the workflow for real-world applications in drug discovery, we cultured hepatic organoids and successfully assessed compound-specific effects.

This approach improves reproducibility, mitigating the variability and handling limitations inherent to manual approaches. It also increases throughput, thereby supporting robust, quantitative organoid compound profiling and efficacy testing for drug discovery applications.

Read the technical note here: https://eu1.hubs.ly/H0v2tmx0

30/04/2026

As research demands more human‑relevant data, bioprinted 3D tissue models are quickly becoming the new standard.

These engineered systems enable more predictive insights across drug toxicity, disease modeling, and mechanistic studies, helping scientists bridge the gap between traditional in vitro methods and real human biology.

In our latest blog, we break down the fundamentals of tissue engineering, why it matters for modern research, and how advanced bioprinting technologies are accelerating progress across the life sciences.

Read now: https://eu1.hubs.ly/H0tZsg-0

Adress

Långfilsgatan 1
Gothenburg
41277

Telefon

+18332355465

Webbplats

http://www.cellink.com/

Aviseringar

Var den första att veta och låt oss skicka ett mail när CELLINK postar nyheter och kampanjer. Din e-postadress kommer inte att användas för något annat ändamål, och du kan när som helst avbryta prenumerationen.

Kontakta Affären

Skicka ett meddelande till CELLINK:

Genvägar

Vill du placera din affär längst upp i Företag-listan i Gothenburg?

Dela

Typ

Bioteknikföretag